INTRODUCTION
In 1967, Ashbaugh et al. described 12 patients with acute tachypnoea, hypoxia and loss of pulmonary compliance which occurred following a variety of precipitating conditions, including trauma, aspiration and pulmonary infection. 1 They remarked on the similarity of this condition to the infant respiratory distress syndrome and postulated a deficiency in surfactant activity which has since been confirmed 2 (although this is not thought to be the primary cause of adult respiratory distress syndrome). They found positive end-expiratory pressure (PEEP) "most helpful in combating atelectasis and hypoxia". They also noted that corticosteroids appeared to be of value in the treatment of fat embolism and viral pneumonia but this has not been born out by further study.
Ashbaugh et al. later defined the Adult Respiratory Distress Syndrome (ARDS) as a condition of respiratory distress with diffuse pulmonary infiltrates on chest X-ray, refractory hypoxaemia and loss of pulmonary compliance, occurring after a precipitating event and excluding chronic lung disease and cardiogenic pulmonary oedema. 3 Murray elaborated on this definition in order to quantify the severity of ARDS and to aid in research and the determination of prognosis. He devised an acute lung injury scoring system based on degree of hypoxaemia, radiological signs and an index of pulmonary compliance (see Table 1 ). His definition also requires identification of the precipitating conditions (the most common being sepsis and gastric acid aspiration) as well as defining the phase of the disease (either acute or chronic). 4 ARDS may also be called non-cardiogenic or mcreased permeability pulmonary oedema and attempts have been made to use pulmonary artery wedge pressure (PAWP) measurements to confirm the diagnosis. For example, Simmons et al. chose a PAWP of greater than 18 mmHg to preclude the diagnosis of ARDS.5 However, up to 20070 of patients with ARDS have associated cardiac dysfunction which may be preexisting or secondary to multiple organ failure. 6 Conversely, patients with cardiogenic pulmonary oedema may have normal PAW Ps, depending on the timing of the measurement, so an arbitrary cut-off for the PAWP is probably inappropriate. Nevertheless, the diagnosis of ARDS is difficult in patients with high cardiac filling pressures.
Ashbaugh et al. recorded a mortality rate of 60070 in patients with ARDS 1 and the reported mortality rate appears to be about the same today. This may reflect different patient groups or a real failure to affect mortality. However, since 1967 there have been great advances in the understanding of the pathogenesis of this condition which provide opportunities for specific intervention. This update includes a brief description of current views about the pathogenesis of ARDS and relates this to recent and potential advances in management. TABLE 1 Components and individual values of the lung injury score.' The' final value is obtained by dividing the aggregate sum by the nU/lib('/" of components used.
Chest X-ray Score 
PATHOGENESIS
ARDS is not a single disease entity but is the pulmonary manifestation of multi-system organ failure (MSOF), sepsis syndrome or septic shock, all of which have the same underlying pathogenic process. Individuals respond to physiological stress in different ways and host characteristics appear to be the major determinant of the occurrence of ARDS. Following exposure to any potentially causative factor only a minority of patients actually develop ARDS (l to 38070). 6 The pathogenesis of ARDS, as of MSOF, is an uncontrolled inflammatory response to a massive insult. This results in vascular endothelial damage, which in the case of ARDS allows pulmonary oedema to occur. A simplified version of the pathogenic events in ARDS has been shown in Figure 1 and is as follows. A stimulus (e.g. exposure to endotoxin) causes macrophages/monocytes to release a number of mediators including tumour necrosis factor (TNF), interleukin-l, -6 and -8 and platelet activating factor (PAF). These in turn cause leucocyte and endothelial activation with leucocyte adhesion to endothelium. The importance of the leucocyte and endothelium in the pathogenesis of MSOF has been realised over recent years. The endothelium is now known to take an active part in the inflammatory process, releasing mediators and modifying leucocyte function. Release of oxygen radicals and proteases from leucocytes, as well as activation of arachidonic acid with release of thromboxane A2, prostacyclin and leukotrienes results in tissue damage. There is also stimulation of fibroblasts with consequent fibrosis. At the same time there are a number of microvascular changes that can result in tissue damage due to microvascular ischaemia, and in an increase in pulmonary vascular resistance which is associated with a poor outcome. PAF is one of a number of mediators that cause platelet aggregation in the pulmonary (as well as systemic) microcirculation. There is coincident activation of coagulation and vasoconstriction. The tendency to intravascular thrombosis is exacerbated by depressed fibrinolytic activity due to decreased levels of tissue plasminogen activator. The consequent increase in pulmonary vascular resistance increases pulmonary artery pressure and can cause right heart failure.
The net result is an increase in shunt fraction, a decrease in pulmonary compliance, an increase in airway resistance, ventilation/perfusion (V/Q) imbalance and pulmonary hypertension.
MANAGEMENT
Management may be divided into preventative, definitive and supportive measures. The stimulus precipitating the inflammatory response may be attentuated, and ARDS (or MSOF) thus prevented, by rapid and adequate resuscitation of the shocked patient. Definitive treatment may include treatment of the underlying cause (e.g. with antibiotics and/or surgery in the case of sepsis).
Further definitive treatment may be aimed at manipulation of the inflammatory process in an attempt to abort the progression to tissue damage. The inflammatory process can be inhibited at various points along the pathogenic pathway and it is likely that, to be successful, a combined attack will be required rather than a single "magic bullet". A number of potential methods are currently under scrutiny although none is as yet available for routine clinical use. These are reviewed later in this paper. Definitive treatment may also be aimed at specific pathological abnormalities found in ARDS. Exogenous surfactant may be administered to replace deficient surfactant or pulmonary microvascular compromise may be reversed with thrombolytics or vasodilators. The use of these will also be reviewed later in the paper.
Once ARDS/MSOF is established, current therapy is limited to general support. One must optimise oxygen delivery (D0 2 ) by increasing inspired oxygen, artificial ventilation, administration of fluids according to PAWP and cardiac index, and administration of blood and inotropes as indicated. Optimising DO z (to supranormal levels) has been shown to improve outcome in critically ill postoperative patients 7 and in septic shock. 8 There is an ongoing debate about the degree of fluid resuscitation appropriate in ARDS. One side of the argument favours relative dehydration of the patient to maintain respiratory function while opponents purport that fluids should be administered to maintain D0 2 , cardiovascular and renal function. Further discussion of this debate is outside the scope of this article. Support of other failing organs and the nutritional status is also important.
Ventilatory support is of paramount importance in the management of the patient with severe ARDS. The aims of ventilatory support are to increase D0 2 in order to support organ function while allowing the lungs time to recover from the acute insult; and avoiding morbidity due to the ventilatory support itself (i.e. barotrauma, oxygen toxicity). There has been recent increasing awareness of the potential iatrogenic effects of artificial ventilation, promoting a search for alternatives to conventional support. There is also a group of patients who die of respiratory failure despite maximal support, encouraging an interest in means of rescuing these patients. Conventional ventilatory support and some alternatives will be reviewed.
VENTILATORY SUPPORT Conventional Therapy
Conventional artificial ventilation of the patient with ARDS is with volume-limited mechanical ventilation (usually synchronised intermittent mandatory ventilation (SIMV)) and PEEP using normal inspiratoryexpiratory ratios.
Traditional use of large tidal volumes and slow rates is said to minimise physiological dead space,9 decrease sense of dyspnoea, 10 allow for gas volume loss by compression, 10 improve arterial oxygen content 11 and maintain adequate ventilation. However, there is evidence from animal studies that artificial ventilation with inflating pressures of as low as 40 cm H 2 0 can result in significant damage in healthy lungs l' with greater risk if there is underlying pathology. 1] There is now a trend towards limiting peak inspiratory pressure either by using smaller tidal volumes or by using pressure-controlled ventilation. Pressurecontrolled ventilation limits peak inspiratory pressure but variations in pulmonary compliance or airway resistance will alter the delivered tidal volume. One study measuring cardiorespiratory variables before and after the institution of pressure-controlled ventilation in patients with ARDS found that D0 2 improved with institution of pressure-controlled ventilation compared with volume-limited ventilation when all other factors were kept equal. 14 However, limitation of inflating pressure as measured at the ventilator does not ensure "safe" intrapulmonary pressures and prevention of barotrauma.
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Permissive Hypercapnia
Again with the aim of limiting iatrogenic lung injury, authors of a recent retrospective, uncontrolled study claimed an improvement in mortality with what was called "permissive hypercapnia". Peak inspiratory pressure was limited to 40 cm H 2 0 using SIMV with small tidal volumes and a rapid respiratory rate. A slow rise in PaC02 was tolerated to allow time for renal compensation for acidosis. The mortality in these patients was significantly better than that predicted by APACHE II. 15 However, this was not a controlled trial, so claims of an improvement in outcome must be viewed with caution, particularly as there are recent reports of improvements in outcome in patients with severe ARDS (see later). However this approach intuitively appears correct, is easy to implement, and has been accepted practice for some time for the management of severe asthma. Its application may be limited by acidaemia if there is associated acute renal failure or sepsis. PEEP PEEP was first described for use in patients with ARDS by Ashbaugh et al. in 1967 1 and remains a mainstay in its management. Since that time it has been reported that prophylactic PEEP does not prevent ARDS 16 and that there is no demonstrated improvement in mortality with its use. 17 However it has a number of benefits when used for the patient with ARDS. It restores functional residual capacity (FRC) to normajl~·21 by recruitment of collapsed alveoli thus increasing Pa02, decreasing inspired oxygen requirements and diminishing the risk of oxygen toxicity. It causes a redistribution of lung water from intraalveolar to the interstitial space'o although it does not decrease total intrapulmonary extravascular lung water. 21 Compliance improves up to a point but deteriorates with high levels of PEEP. 22 It also decreases shunt'II.21 and improves V/Q matching." PEEP also has potential problems. It can decrease cardiac output by a number of mechanisms. These include: a decrease in venous return 24 ,2,; pulmonary compression of the left atrium; increased pulmonary vascular resistance 24 . 26 possibly causing an increase in right ventricular end-diastolic volume and a decrease in left ventricular distensibility (ventricular interdependence) 27; and tension pneumothorax. PEEP also increases the potential for barotrauma 28. Appropriate PEEP There has been much discussion about the best method to determine the appropriate level of PEEP in the individual patient and a number of authors have published recommendations (see Table 2 ). Unfortunately each method has limitations, mainly because of shortcomings or practical difficulties in the measurement required. At shunt fraction of 15 01 0 aim to reduce PI02 to al'oid O\lgen toxicity.'" "PRHERRED PEEP" At maximum oxygen delilery. using fluid challenges to maintain cardiac output.·" "IDEAl. PEEP"
At minimal PaC02-P[TC02 gradient. aloids depression of cardiac output and increase in dead space. " "I.EAST PEEP"
The least PEEP required to maintain FI02 at 0.5
and Pa02 > 59 mm Hg."
Unconventional Strategies: Inverse Ratio Ventilation
There is a group of patients with ARDS who require unacceptably high levels of inspired oxygen concentrations (F,02), PEEP and peak inspiratory pressures to maintain oxygenation and ventilation. Different strategies have been tried in an effort to prevent iatrogenic lung damage. One of these methods is to reverse the inspiratory/expiratory (I:E) ratio from the usual 1:2 up to a maximum of about 4:1, although in practice I:E ratios above 2:1 are rarely used.
Inverse ratio ventilation (IRV) can be applied with either volumeor pressure-controlled ventilation. During volume controlled ventilation peak inspiratory flow rates can be decreased or an inspiratory pause may be added. Many studies suggest that IRV can enhance oxygenation after conventional ventilation has failed in most (but not all) patients with ARDS3335. It also acts to decrease mean peak inspiratory pressure, PaC02, minute ventilation requirements and physiological dcadspace, and improves VlQ mismatch. However, it increases mean airway pressure. 35 There are no controlled studies on outcome.
The mechanism of the improvement in oxygenation with the use of IRV is alveolar recruitment, but how it does this is not known. It may allow a greater homogeneity of ventilation to poorly ventilated lung units because of a longer time for gas delivery. An alternative explanation is that it acts by the application of auto-PEEP, functioning in a similar way to applied PEEP. Auto-PEEP is a common occurrence in ventilated patients, especially those with obstructive lung disease 36J7 , but can also be seen in any ventilated patient. 36 ,J" It is a positive alveolar pressure that occurs at the end of expiration. In IRV it occurs because there is insufficient time for full expiration to occur, so that the next breath begins before alveolar pressure has reached atmospheric pressure. It acts in the same way as applied PEEP by increasing FRC, and can also depress cardiac output. Cole found that when he compared PEEP with an IRV of 4:1 and matched them to maintain the same end-expiratory volume there was no difference in shunt fraction, suggesting that IRV was having the same effect as applied PEEP. 38 Problems of IRV include a requirement for neuromuscular blockade (particularly when high ratios are used)39 and cardiovascular compromise due to auto-PEEP. However this occurs only occasionally in clinical practice with low ratios, e.g. 2:1. 39 An advantage of IRV , is its ease of implementation when using most modern intensive care ventilators.
High-Frequency Ventilation
In contrast with the potential of using I RV, highfrequency ventilation has not proven beneficial in patients with ARDS. The aim of high-frequency ventilation is ventilation without large volume excursions thereby avoiding high airway pressures and the resulting barotrauma. Of the various types of high-frequency ventilation, only high-frequency jet ventilation (HFJV) has been critically examined (in four controlled clinical trials). The overall consensus was that HFJV showed no advantage over conventional ventilation in this group of patients 40 . 43 and may be less effective in patients with non-compliant lungs. 42 Despite reductions in proximal airway pressures, barotrauma is still a significant potential complication.
HFJV has been used successfully in patients with bronchopleural fistulae (BPF) not associated with ARDS.44 However, a recent study looking at patients with BPF secondary to ARDS found the use of HFJV to be disappointing. Bishop et al. reported seven patients who were crossed over from conventional to HFJV. This resulted in an increase in leak and deterioration in oxygenation in six out of seven. 45
Prone Position
In 1976 Piehl et al. showed that changing mechanically ventilated patients with acute lung injury from supine to prone posture improved oxygenation. 46 Since then a total of 24 patients have been reported in the literature, of which 79!J!o responded to the prone posture with an improvement in oxygenation. 39 The improvement persisted throughout the time spent prone. This is probably due to an improvement in VlQ imbalance but cannot be explained by improved ventilation of healthier dependent tissue, as the lung does not appear to be more damaged posteriorly. Perfusion seems to be more evenly distributed when prone in diseased or healthy lung. 47 
Artificial Methods of Gas Exchange
With the continuing occurrence of hypoxia refractory to the above regimens, new methods have been investigated that could potentially allow time for the damaged lungs to recover, while supporting oxygen requirements and avoiding barotrauma and oxygen toxicity. Artificial methods of gas exchange were the next logical step and thus extracorporeal membrane oxygenation (ECMO), extracorporeal CO 2 removal (ECC02R) and intravascular oxygenation (lVOX) were conceived.
ECMO
In 1979, a multicentre controlled trial was reported by Zapol et al using ECMO for severe acute respiratory failure. 48 The study involved 90 patients and a venoarterial circuit. There were specific criteria of severe lung injury based on blood gases for entry into the trial. Survival rate at two weeks was the same in both groups (ECMO 9.5070 and control 8.3070 ). ECMO caused frequent complications including thrombocytopenia, increased blood and plasma infusion requirements and was labour intensive.
ECMO may still have a place for management of certain patients. It can be used to tide patients over until a curative procedure, e.g. lung transplant, can be performed. ECMO is currently considered to be indicated for newborns with respiratory distress with predicted mortality rates, based on clinical parameters, of > 80070 if conventional therapy is used. The Neonatal ECMO Registry reports an 83070 survival rate in this group which compares favourably with the 20070 survival in historical controls. There is an incidence of neurological injury, possibly due to internal jugular and common carotid ligation and/or the use of heparin. Long-term complications are as yet unknown. There is still some doubt regarding the proven efficacy of ECMO in this context based on the fact that the only controlled trials reported can be criticised on the basis of their methods of randomisation.
With the disappointment following the failure of ECMO to influence outcome, alternative forms of extracorporeal gas exchange were examined. The next method to gain popularity was ECC0 2 R. In contrast to ECMO, venovenous access is used which provides oxygenated blood to the lungs first. This has the theoretical benefit of improving lung recovery. This method removes 200-300 mllmin CO 2 , and provides 20-30070 of oxygen requirements. The remainder of the oxygen is provided by low-frequency positive-pressure ventilation (LFPPV) with [3] [4] [5] 
breaths per minute at a
Anaesthesia and Intensive Care. Vol. 22, No. 3, June. 1994 peak pressure of 45 cm H 2 0 with PEEP and inspired oxygen concentration adjusted as required and/or apnoeic oxygenation via a cannula to the carina supplying 200-300 mllmin oxygen. 49 Animal models have shown an increased survival with the use of ECC0 2 R. For example, in one sheep model with mild lung injury survival increased from 27 to 82070 5°. There have been 115 reported instances of use of ECC0 2 R in humans with a pooled survival rate of about 50070. Many of the 115 patients satisfy the ECMO criteria of severe lung injury (8.3070 survival in Zapol's study), 48 so the 50070 survival rate was greeted with enthusiasm. 49 However there is a recent study reporting a 45070 survival out of 51 patients with severe ARDS as defined by ECMO criteria 51. This was part of a controlled trial on the use of ECC0 2 R. The authors found no improvement in outcome with the use of ECC0 2 R-LFPPV compared with conventional positive pressure ventilation. This study suggests that the survival in this group of patients is better than that reported in Zapol's trial in 1979 and emphasises the importance of controlled trials rather than the use of historical controls in the examination of new treatment modalities. Overall mortality rates for ARDS remained unchanged at 53070. Of the 28 deaths in the severe group, 16 (57070) died of respiratory failure and 8 of overwhelming sepsis.
I VOX
Intravascular oxygenation (I VOX) will soon be released in the USA and is currently under investigation in Australia. It is a device, introduced into the inferior vena cava, which is made up of many oxygen-filled hollow filaments across which gas exchange (including some CO 2 removal) occurs. Gas exchange is not as great as that seen with the use of ECMO so IVOX can supplement but does not supplant artificial ventilation. It has been used safely in humans with ARDS but its effect on outcome is yet to be determined 52.
Specific Therapy
Only 16070 of deaths in patients with ARDS are due to respiratory failure 53 so improvement in ventilatory support may only be expected to affect outcome in this small group. It is hoped that blockade of the pathogenic pathway at one or a number of points will improve outcome in the group as a whole. Outlined below are some of the potential mechanisms for this blockade.
Anti-Endotoxin Antibodies
The use of a monoclonal anti-endotoxin antibody, HA-lA, was examined in a multicentre trial involving 543 patients with sepsis syndrome 54. It was found to improve survi\'al in a specific subgroup of patients, i.e. those with gram-negative septicaemia and pmitive blood cult ures. In t his subgroup 51 (J7o of controls sur-\i\ed compared with 70% given HA-lA. At present, till: clinical use of HA-lA is limited by the fact that this subgroup cannot be identified early enough to rcnder the treatment effective. When given to all patients with sepsis syndrome in the study there was nu significant improvement in the mortality overall. Administration of HA-lA also did not imnrove survival in the subgroup of patients with ARDS". Unfortunately the drug comes at huge cost. A second multi-(Clltre trial has been aborted because early results did not ~upport the beneficial effects of HA-lA. Currently enort is directed at early identification of gramnegative sept icaemia.
High-Dose Steroids
The theoretical benefits of steroids are that they inhibit activation of complement. inhibit complement induced neutrophil aggregation, inhibit macrophage production of tumour necrosis factor and inhibit the production of arachidonic acid. Early animal studies showed benefit when steroids were given before or shortly after the infusion of endotoxin but no benefit when given after the endothelial permeability defect had occurred. Since then clinical trials have failed to show a benefit with the use of steroids for ARDS or sepsis. Specifically, steroids caused an increase in mortality in patients with sepsis or septic shock '", did not prevent ARDS in sepsis syndrome ,-and did not improve pulmonary function or outcome after ARDS was established ss. There remains a possibility of their efficacy in the fibrotic phase of ARDS based on three uncontrolled reports in the literature which suggest a benefit. "U'(), 61 Late deaths in ARDS are associated with pulmonary fibrosis (55%) and with sepsis/MSOF (69070) (often due to pneumonia). Both fibrosis and sepsis present with an identical clinical picture (i.e. sepsis syndrome, with purulent sputum, fever, leukocytosis, changes on chest X-ray, deterioration in respiratory function and a haemodynamic picture of sepsis). Diagnosis of pulmonary infection is difficult but is imperative if the use of steroids is considered. Currently the safest, most reliable method is believed to be by collection of distal airway secretions by bronchoscopy. Open lung biopsy is recommended by Meduri et al. 0] although this method did not identify any more infections than bronchoscopy in their study. Open lung biopsy is said to be safe" but the inherent danger of this technique in the ventilated patient on high peak impiratory pressures and PEEP renders it unpopular.
The above studies. combined. cite an 82(}!o survi\al in a total of 28 pat ients given steroids with pulmonary fibrosis secondary to ARDS. They are uncontrolled but the reported improvement in respiratory function temporally related to administration of steroids is interesting. High-dose steroids (2-3 mg/kg/day methylprednisolone) were used in the most recent study and had to be continued for some time. (,] Meduri et al. recommend weekly surveillance for infection with bronchoscopy for those on steroids. 6 ] lc) confirm the benefits of the use of steroids in the fibrotic phase of ARDS a multicentre trial is required.
Prostaglandin E, (PGE,)
PGE I has a !lumber of effects that could be potentially beneficial in the treatment of ARDS. It is a vasodilator, is anti-in flammatory, inhibits platelet aggregation, inhibits neutrophil chemotaxis, prevents oxygen radical and lysosomal release by neutrophils and prevents macrophage activation. It has been studied for use in the treatment of ARDS in a multicentre trial involving 100 patients. It was found to decrease SVR, blood pressure, pulmonary vascular resistance and to increase cardiac index, DO:, and oxygen consumption but showed no improvement in outcome. It also caused diarrhoea, hypotension, fever and supraventricular arrhythmias. 63 
Con t i nuolls Haelllodialysi5
Most of the mediators involved in the pathogenesis of ARDS and MSOF have a molecular weight of < 1000 Dalton and are therefore easily removed by the dialysis filters used for continuous dialysis in ICU. There have been uncontrolled reports of the early use of dialysis in small numbers of patients with ARDS claiming improvements in respiratory function and outcome.O-IJ" Again confirmation of these preliminary reports by a multicentre trial is required.
Inhibition of Mediators
As described above, tumour necrosis factor (TNF) is considered an important cytokine in the pathogenesis of ARDS and MSOF. TNF can be detected in only 36(}/0 of patients with septic shock, possibly because of its evanescent nature. 00 It is found in both grampositive and gram-negative sepsis. The presence of TNF is associated with a higher incidence and severity of ARDS and increased mortality. " Anti-TNF antibody prevents septic shock and death in baboons subsequently given endotoxin. 07 Preliminary studies in humans with established septic shock found that administration of anti-TNF increased blood pressure allowing withdrawal of inotropes,6i and improved ventricular function and arterial oxygenation. 69 A multicentre controlled trial is in progress. An alternative method of blocking TNF activity with soluble circulating TNF receptor which binds to and inactivates circulating TNF is also under investigation. 70 Attention is also directed at other mediators involved in the inflammatory process. Antagonists to interleukin-l receptors have been found to attentuate haemodynamic changes, reduce the severity of .lactic acidosis and improve survival in an animal model of septic shock. 71 Studies in humans are underway. PAF receptor antagonists are also being studied. Antagonists to PAF receptors, when given to animals prior to endotoxin induced shock, protect against pulmonary hypertension, oliguric renal failure, gastrointestinal damage and decreased cerebral blood flow. 72 
Anti-Adhesion Molecule Antibodies
Neutrophil adhesion to endothelium is an important early step in the inflammatory process and is mediated by a multitude of adhesion molecules. There is extensive research going on at present in this area with attempts to block adhesion with monoclonal antibodies to adhesion molecules. There is evidence in animals and humans that adhesion molecules are involved in the pathogenesis of MSOF and ARDS but attempts at inhibition in an effort to control the process are, at present, highly preliminary. More progress has been made in reperfusion injury, particularly in hypovolaemic shock, where adhesion has been blocked in animal studies with an improvement in mortality. 73 Human studies using mono clonal antibodies to adhesion molecules after trauma associated with hypovolaemic shock are currently underway.
Pentoxyfilline
Pentoxyfilline is a phosphodiesterase inhibitor which acts to inhibit neutrophil release of lysosomal enzymes, release of oxygen radicals, and adherence to endothelium. It also inhibits macrophage release of TNF. 7. In animal models it has been shown to prevent experimental lung injury and improve survival. 74, 75, 76 There are no published studies in humans as yet.
Antioxidants
As free oxygen radicals released from neutrophils may contribute to pulmonary injury in ARDS, oxygen radical scavengers have been investigated as a treatment modality for several years. However, in vivo work has been disappointing. Superoxide dismutase given to pigs and sheep with ARDS proved ineffective in reversing the haemodynamic or permeability effects of endotoxin. 77, 78 Catalase, dimethyl urea and desferrioxamine may have some beneficial effects. 77 ,78,79,80 Anaesthesia and Intensive Care, Vol. 22, No. 3, June, 1994 One free radical scavenger, N-acetylcysteine (NAC) has been studied clinically after preliminary trials appeared to show some promise. Patients with ARDS have depressed concentrations of plasma and red cell glutathione which are increased following administration of NAC. A pilot study (n = 20) revealed an increase in D0 2 , lung compliance and resolution of lung oedema following administration of NAC which was associated with an increase in cardiac output. 81 However a subsequent study on 66 patients with ARDS failed to show a difference between treatment and control groups with regard to Pao2/FI02 ratio, pulmonary compliance, chest X-ray or survival. 82 
Prostaglandin Inhibitors
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase and so decrease synthesis of thromboxane-A2 and prostacyclin. This results in a decrease in platelet and neutrophil aggregation and a decrease in leucocyte lysosmal and oxygen radical release. A number of NSAIDs are being studied for use in ARDS and sepsis. Several studies on the use of ibuprofen in animal models of sepsis have shown that it prevents or attentuates pulmonary hypertension, can improve survival and when combined with H I and H2 blockers, can prevent the increased pulmonary capillary endothelial permeability [83] [84] [85] [86] when given prior to the insult.
Numbers of patients in clinical trials on NSAIDs are as yet small and the results are conflicting. A small (n = 29) randomised, double-blind, multicentre, clinical trial on the use of ibuprofen in sepsis revealed no benefit on haemodynamic or respiratory variables although the absorption of the drug given rectally may have been inadequate. 87 Another study examined 15 patients with sepsis syndrome given ibuprofen or placebo rectally 4 hourly for 3 doses. Shock reversed in 880/0 of the treated group versus 430/0 of controls (P=O.l2). Ibuprofen decreased minute ventilation requirements (P=0.03) but there was no improvement in oxygenation. 88 A small (n = 10) placebo controlled trial in humans with ARDS reported a significant improvement in oxygenation and shunt fraction following administration of indomethacin. 89 These studies support the need for further investigation into the use of NSAIDs for the treatment of ARDS. They did not show any complications due to the use of NSAIDs.
MODIFICATION OF THE MICROVASCULAR CHANGES OF ARDS
As the increase in pulmonary vascular resistance observed in ARDS is associated with a poor outcome, attempts have been made to reverse this and thereby improve oxygenation and relieve right heart strain.
Sirric Oxide
"Endothelium derived relaxing factor" is a potent ,asodilator which has recently been identified as nitric uxide (NO) . It is produced by endothelial cells and is important in the acute and continuous control of vascular tone. Sepsis is associated with an increase in the systemic production of NO which may be one mode of ll1ediation of the low systemic vascular resistance (SVR) found in scptic shock. In the pulmonary vasculature its production or activity may be decreased, contributing to the pulmonary vasoconstriction seen in ARDS. It has recently been the subject of a comprehen.sin: review. '10 Potential manipulation of NO involves its inhibition systemically which may reverse vasodilation and hypolemion, while its administration to the pulmonary \ ascular system may reverse the vasoconstriction. Inhalcd NO has been administered, in doses of up to 80 parts per million, to lambs with pulmonary hypertemion resulting in a selective decrease in pulmonary artery pressure with no change in systemic blood pressure. ' ) I NO is metabolised locally by haemoglobin and so does not reach the systemic circulation. When inhaled, it is only delivered to the ventilated parts of the lung and so improves ventilation/perfusion imbalance and increases Pa02' In the normal subject it \\ould have no effect on oxygenation. A recent study in humans with ARDS confirms these animal findings. '" Larger trials to determine effects on outcome are yet to be performed.
Prosta(vC/in (PG!])
Small groups of patients with ARDS have been given PGI 2 infusiom. This has resulted in a decrease in pulmonary artery pressure and an increase in cardiac index, with a possible improvement in right ventricular function. There was an increase in venous admixture but no change in Pa02' However PGI 2 has not yet been examined in a controlled trial, causes hypotension and can cause bleeding. 4l
Throlll holy! ics
As microvascular thrombosis plays an important part in the pathogenesis of ARDS and particularly of the associated pulmonary hypertension, there has been some interest in the use of thrombolytics for prevention and treatment. Both tissue plasminogen activator and urokinase have heen used successfully in an animal model after trauma to prevent ARDS and death. 94 
411/1 i (rine
Almitrine is a piperazine derivative which increases Pa02 and decreases PaC02 in patients with obstructive lung disease with sustained effect. It was recently compared to 10 cm H 2 0 PEEP in a controlled trial in patients with ARDS. Almitrine and PEEP were found to have a similar beneficial effect on oxygenation, but the use of PEEP was associated with a decrease in blood pressure. 95 The mode of action of almitrine is unknown, but it probably improves the perfusion side of VlQ mismatch as opposed to PEEP affecting ventilation. It may enhance hypoxic pulmonary vasoconstriction thus increasing pulmonary vascular tone and pulmonary artery pressure, so in theory may be deleterious. This has only been reported in a single study and needs more work.
Surfactant
Surfactant lowers alveolar surface tension and increases lung compliance. In ARDS there are changes in surfactant composition and function. Surfactant has been administered successfully in animal models of ARDS to improve oxygenation and lung compliance.
Most of the clinical work on the therapeutic use of surfactant has been performed in the infant respiratory distress syndrome. Interpretation of the various studies is complicated by the fact that different types of surfactant have been used. Surfactant types include natural, modified natural, synthetic, and synthetic natural. It has now been shown that surfactant used both prophylactically and for the treatment of established respiratory distress in infants will decrease respiratory complications and improve outcome. 96 It appears that natural surfactant is superior to artificial. 97 Dose and delivery system are problems to be overcome. Clinical studies in adults are yet to be published.
PROGNOSIS
Both early and late deaths in ARDS are mainly due to sepsis (late sepsis tends to be due to pulmonary infection), 98 Patients with ARDS have poorly functi0:1ing neutrophils in their lungs which may be the reason for the high incidence of pulmonary infections. 99 A recent study reported an overall mortality rate of 59070 associated with ARDS. 100 However, prognosis varies with the underlying condition and associated organ dysfunction. ARDS due to fat embolism has a 90070 survival 101 while following bone marrow transplantation or in association with hepatic failure it has a 100070 mortality. 102, 103 A high pulmonary vascular resistance and low pulmonary compliance are also associated with poor prognosis while survivors tend to have a higher D0 2 • 104 For those who survive ARDS the outlook regarding long-term respiratory function is good. At one year, more than 50070 of patients have a measurable decrease in diffusing capacity, forced vital capacity or forced expiratory volume in the first second but only a minority have any impairment to daily activity. 105 The apparent stasis of mortality rate of patients with ARDS since the report by Ashbaugh et al in 1967 requires a final comment. They reported 12 patients aged less than 50 years whose mortality rate was about 60070. 1 Although the overall mortality rate is the same today, our patient population has aged significantly compared with 25 years ago, and may also be significantly sicker. Outcome from ARDS is affected by age, with a reported mortality in one study of 12% in those < 60 years and 69% in those > 60 years. 106 Comparison of studies on ARDS is limited by a number of difficulties including diagnosis and assessment of severity of ARDS. Therefore no statement can confidently be made about a change (or lack thereof) in the mortality rate with time.
CONCLUSION
Significant recent advances have been made into understanding the pathogenesis of ARDS. This syndrome is now understood to be part of a diffuse process that results from a complicated cascade of events which follows an initial precipitating incident. Artificial ventilation and PEEP are still important components of supportive therapy. Attention has been turned to prevention of iatrogenic lung damage by use of pressure-controlled ventilation, permissive hypercapnia and possibly by early use of an artificial means of gas exchange. For those with resistant hypoxia, further options are limited to inverse ratio ventilation and prone positioning to improve oxygenation. Artificial methods of gas exchange (ECMO, ECC0 2 R, IVOX) are yet to prove beneficial to outcome.
As respiratory failure itself causes only a fraction of deaths due to ARDS, attention is directed towards manipulation of the inflammatory cascade in the hope of halting the progression of the disease. Trials on the use of steroids and PGE 1 have been disappointing. The results of further clinical trials on the use of continuous haemodialysis, anti-adhesion molecule and TNF antibodies, interleukin-l and platelet activating factor receptor antagonists, steroids for pulmonary fibrosis, pentoxyfilline, prostaglandin inhibitors, inhaled nitric oxide, thrombolytics, almitrine, and surfactant are awaited.
